Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 12

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 6 7 8 9 10 11 < 12 > 13 14 15 16 17 18 .. 184 >> Следующая

34. Stuart RA, Kornman LH, McHugh NJ. A prospective study of pregnancy outcome in women screened at a routine antenatal clinic for anticar-diolipin antibodies. Br J Obstet Gynaecol 1993; I00: 599—600.
35. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, Emlen W. Antiphos-pholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med 1994; 120: 470—475.
36. Muir KW, Squire IB, Alwan W. Anticar-diolipin antibodies and cerebral infarction (letter, comment). J Neural Neurosurg Psychiatry 1994; 5: 253—254.
37. Chakravart KK, AI-Hillaw AH, Byron MA, Durkin CJ. Anticardiolipin antibody associated ischemic strokes in elderly patients without systemic lupus erythematosus. Age Ageing 1990; 19: 114—118.
38. Candore G, Di Lorenzo G, Mansueto P, et al. Prevalence of organ-specific and non organ specific autoantibodies in healthy centenarians. Mech Ageing Dev 1997; 94: 183—190.
39. Richaud-Patin Y, Cabiedes J, Jakez-Ocampo J, et al. High prevalence of protein-dependent and protein-independent antiphospho-lipid and other autoantibodies in healthy elders. Thromb Res 2000; 99: 129—133.
40. Caporali R, Ravelli A, De Gennaro F, et al. Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. Ann. Rheum Dis 1991; 50: 599—601.
41. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997—1002.
42. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91:23—27.
43. Levine SR, Brey RL, Joseph CLM, Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992; 23: Suppl 1:1—29.
44. Runchey SS, Folson AR, Tsai MY et al. Anticardiolipin antibodies as a risk for venous thromboembolism in a population-basedprospective study. Br J Haematol 2002; 119: 1005— 1010.
45. Ahmed E, Stegmayt B, Trifunovic J, et al. Anticardiolipin antibodies are not an independent risk factor for stroke. An incident case-reference study nested within THE MONICA and Vasterbotten Cohort Progecy. Stroke 2000; 31: 1289—1293.
46. Wachl DG, Guillemiv F, de Maistre E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmine disease or previous thrombosis. Lupus 1998; 7:15
47. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer>40 GPL and risk of subsequent thrombo-occlusive events and death. Stroke 1997; 28: 1660—1665.
48. Escalante A, Brey RL, Mitchell BD, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among
SHS-OOO4.qxd 21.11.2006 16:56 Page 34
4
Насонов Е.Л. Антифосфолипидный синдром.
patients with systemic lupus erythematosus. Am J Med 1995; 98: 559—565.
49. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530—536.
50. Brey RL, Abbott RD, Curb Jd, et al. Beta2-glycoprotein-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction. The Honolulu Heart Program. Stroke 2001; 32: 1701—1706.
51. Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33: 2396.
52. Tanne D, DOlhaberriague L, Trivedi AM, et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002; 21: 93— 99.
53. Schved JE, Dupuy-Fons C, Biron C, et al. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) study. Haemostasis 1994; 24:175—182.
54. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and anti-phospholipid antibodies. Dement Geriatr Cogn Disord 2000; 11: 36—8.
55. Juby A, Davis P, Genge T, McEllhaney J. Anticardiolipin antibodies in two eldery subpopu-lations. Lupus 1995; 4: 482—485
56. Tietjen GE, Day M, Norris L et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology 1998; 50:1433— 40.
57. Verrotti A, Cieri F, Pelliccia P, Morgese G, Chiarelli F. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Lab Res 2000; 30: 109—11.
58. Cimaz R, Romeo A, Scarano A, et al. Prevalence of anticardiolipin. anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002; 43: 52—59.
59. Schwartz M, Rochas M, Weller B et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998; 59: 20—3.
60. Kenet G, Sadetzki S, Murat H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factor for ischemic stroke in children stroke 2000; 31: 1283—1288.
Предыдущая << 1 .. 6 7 8 9 10 11 < 12 > 13 14 15 16 17 18 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed